Status:
COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Groupe Hospitalier Pitie-Salpetriere
Conditions:
Carnitine Palmitoyltransferase II Deficiency
Very Long Chain Acyl Coa Dehydrogenase Deficiency
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-d...
Detailed Description
Background and research aim: Carnitine palmitoyltransferase II (CPTII) and very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies are the two most common inherited disorders of mitochondrial fat...
Eligibility Criteria
Inclusion
- CPT II or VLCAD deficiency
Exclusion
- Competing disorders
- Liver or kidney disease
- Allergy towards fibrates
- Pregnancy and breastfeeding
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00983788
Start Date
October 1 2009
End Date
September 1 2011
Last Update
May 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuromusculare Research Unit, Rigshospitalet
Copenhagen, Copenhagen, Denmark, 2100